Inhibition of VEGF mRNA by 2′-O,4′-C-ethylene-bridged nucleic acids (ENA®) antisense oligonucleotides and their influence on off-target gene expressions

Nucleosides, Nucleotides and Nucleic Acids

Volumn 25, Issue 4-6, 2006, Pages 503-521

  Morita, Koji ^a   Yamate, Koji ^a   Kurakata, Shin Ichi ^a   Abe, Koji ^a   Watanabe, Kenji ^a   Koizumi, Makoto ^a   Imanishi, Takeshi ^b  

^a DAIICHI SANKYO CO   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

2 ,4 BNA LNA; Antisense; BLAST; ENA; RT PCR; VEGF

Indexed keywords

2' O 4' C ETHYLENE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGODEOXYNUCLEOTIDE; MESSENGER RNA; NUCLEIC ACID; RIBONUCLEASE H; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC DATABASE; LUNG CARCINOMA; MALE; MOLECULAR STABILITY; NONHUMAN; NUCLEIC ACID ANALYSIS; NUCLEOTIDE SEQUENCE; RAT;

ANIMALS; BASE SEQUENCE; GENE EXPRESSION REGULATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; OLIGONUCLEOTIDES, ANTISENSE; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ENA;

EID: 33747624369     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770600684191     Document Type: Article

References (33)

1. Scherer, L. J.; Rossi, J. J. Approaches for the sequence-specific knockdown of mRNA. Nature Biotechnology 2003, 21, 1457-65.
2. Schlingensiepen, R.; Schingensiepen, K.H. Antisense oligonucleotides- highly specific tools for basic research and pharmacotherapy, in Antisense-from Technology to Therapy, eds. Schlingensiepen, R.; Brysch, W.; Schingensiepen, K.H. Black Sciences Ltd., Berlin, 1997, pp 3-28.
3. Levin, A. A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochimica et Biophysica Acta 1999, 1489, 69-84.
4. Aboul-Fadl, T. Antisense oligonucleotides: the state of the art. Current Medicinal Chemistry 2005, 12, 2193-2214.
5. Obika, S.; Nanbu, D.; Hari, Y.; Morio, K.; In, Y.; Ishida, T.; Imanishi, T. Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3′-endo sugar puckering. Tetrahedron Letters 1997, 38, 8735-8738.
6. Koshkin, A.A.; Singh, S.K.; Nielsen, P.; Rajwanshi, V.K.; Kumar, R.; Meldgaard, M.; Olsen, C.E.; Wengel, J. LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 1998, 54, 3607-3630.
7. McTigue, P.M.; Peterson, R.J.; Kahn, J.D. Sequence-dependent thermodynamic parameters for locked nucleic acid (LNA)-DNA duplex formation. Biochemistry 2004, 43, 5388-5405.
8. Morita, K.; Hasegawa, C.; Kaneko, M.; Tsutsumi, S.; Sone, J.; Ishikawa, T.; Imanishi, T.; Koizumi, M. 2′-O,4′-C-Ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorganic Medicinal Chemistry Letters 2002, 12, 73-76.
9. Morita, K.; Takagi, M.; Hasegawa, C.; Kaneko, M.; Tsutsumi, S.; Sone, J.; Ishikawa, T.; Imanishi, T.; Koizumi, M. Synthesis and properties of 2′-O,4′-C-ethylene-bridged nucleic acids (ENA) as effective antisense oligonucleotides. Bioorganic & Medicinal Chemistry 2003, 11, 2211-2226.
10. Takagi, M.; Morita, K.; Nakai, D.; Nakagomi, R.; Tokui, T.; Koizumi, M. Enhancement of the inhibitory activity of oatp antisense oligonucleotides by incorporation of 2′-O,4′-C-ethylene-bridged nucleic acids (ENA) without a loss of subtype selectivity. Biochemistry 2004, 43, 4501-4510.
11. Koizumi, M.; Morita, K.; Daigo, M.; Tsutsumi, S.; Abe, K.; Obika, S.; Imanishi, T. Triplex formation with 2′-O,4′-C-ethylene-bridged nucleic acids (ENA) having C3′-endo conformation at physiological pH. Nucleic Acids Research 2003, 31, 3267-3273.
12. Yagi, M.; Takeshima, Y.; Surono, A.; Takagi, M.; Koizumi, M.; Matsuo, M. Chimeric RNA and 2′-O,4′-C-ethylene-bridged nucleic acids have stronger activity than phosphorothioate oligodeoxynucleotides in induction of exon 19 skipping in dystrophin mRNA. Oligonucleotides 2004, 14, 33-40.
13. Surono, A.; Van Khanh, T.; Takeshima, Y.; Wada, H.; Yagi, M.; Takagi, M.; Koizumi, M.; Matsuo, M. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon. Human Gene Therapy 2004, 15, 749-757.
14. Koizumi, M. 2′-O,4′-C-Ethylene-bridged nucleic acids (ENA™) as next-generation antisense and antigene agents, Biological & Pharmaceutical Bulletin 2004, 27, 453-456.
15. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nature Medicine 2003, 9, 669-676.
16. Hasan, J.; Jayson, G.C. VEGF antagonists. Expert Opinion Biological Therapy 2001, 1, 703-718.
17. Nomura, M.; Yamagishi, S.; Harada, S.; Hayashi, Y.; Yamashima, T.; Yamashita, J.; Yamamoto, H. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. Journal of Biological Chemistry 1995, 270, 28316-28324.
18. Masood, R.; Cai, J.; Zheng, T.; Smith, D.L.; Naidu, Y.; Gill, P.S. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proceedings of the National Academy of Sciences USA 1997, 94, 979-984.
19. Robinson, G.S.; Pierce, E.A.; Rook, S.L.; Foley, E.; Webb, R.; Smith, L.E. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proceedings of the National Academy of Sciences USA 1996, 93, 4851-4856.
20. Driver, S.E.; Robinson, G.S.; Flanagan, J.; Shen, W.; Smith, L.E.; Thomas, D.W.; Roberts, P.C. Oligonucleotide-based inhibition of embryonic gene expression. Nature Biotechnology 1999, 17, 1184-1187.
21. Obika, S.; Uneda, T.; Sugimoto, T.; Nanbu, D.; Minami, T.; Doi, T.; Imanishi, T. 2′-O,4′-C-Methylene bridged nucleic acid (2′,4′-BNA): synthesis and triplex-forming properties. Bioorganic & Medicinal Chemistry 2001, 9, 1001-1011.
22. Koizumi, M.; Koga, R.; Hotoda, H.; Momota, K.; Ohmine, T.; Furukawa, H.; Agatsuma, T.; Nishigaki, T.; Abe, K.; Kosaka, T.; Tsutsumi, S.; Sone, J.; Kaneko, M.; Kimura, S.; Shimada, K. Biologically active oligodeoxyribonucleotides. IX. Synthesis and anti-HIV-1 activity of hexadeoxyribonucleotides, TGGGAG, bearing 3′- and 5′-end- modification. Bioorganic & Medicinal Chemistry 1997, 5, 2235-2243.
23. Monia, B.P.; Lesnik, E.A.; Gonzalez, C.; Lima, W.F.; McGee, D.; Guinosso, C.J.; Kawasaki, A.M.; Cook, P.D.; Freier, S.M. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. Journal of Biological Chemistry 1993, 268, 14514-14522.
24. Kurreck, J.; Wyszko, E.; Gillen, C.; Erdmann, V.A. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Research 2002, 30, 1911-1918.
25. Crooke, S.T.; Lemonidis, K.M.; Neilson, L.; Griffey, R.; Lesnik, E.A.; Monia, B.P. Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochemical Journal 1995, 312, 599-608.
26. Sohail, M.; Hochegger, H.; Klotzbucher, A.; Guellec, R.L.; Hunt, T.; Southern, E.M. Antisense oligonucleotides selected by hybridization to scanning arrays are effective reagents in vivo. Nucleic Acids Research 2001, 29, 2041-2051.
27. Patzel, V.; Steidl, U.; Kronenwett, R.; Haas, R.; Sczakiel, G. A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability. Nucleic Acids Research 1999, 27, 4328-4334.
28. Mathews, D.H.; Sabina, J.; Zuker, M.; Turner, D.H. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. Journal of Molecular Biology 1999, 288, 911-940.
29. Lima, W.F.; Crooke, S.T. Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry 1997, 36, 390-398.
30. Cho, Y.S.; Kim, M.K.; Cheadle, C.; Neary, C.; Becker, K.G.; Cho-Chung, Y. S. Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proceedings of the National Academy of Sciences USA 2001, 98, 9819-9823.
31. Cho-Chung, Y.S.; Becker, K.G. A genome-wide view of antisense. Nature Biotechnology 2003, 21, 492.
32. Fisher, A.A.; Ye, D.; Sergueev, D.S.; Fisher, M. H.; Shaw, B. R.; Juliano, R. L. Evaluating the specificity of antisense oligonucleotide conjugates. A DNA array analysis. Journal of Biological Chemistry 2002, 277, 22980-22984.
33. Bilanges, B.; Stokoe, D. Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi. Biochemistry Journal 2005, 388, 573-583.